The Magazine for Sleep Professionals
Friday, September 25, 2026
Specific types of gut bacteria may increase or decrease the risk for insomnia, while insomnia itself may in turn alter the abundance of certain gut bacteria, a new study showed. However, outside experts challenged the investigators’ assertion that the link is causal. Investigators identified 14 groups of bacteria associated with increased […]
EnsoData has announced a collaboration with Takeda to jointly develop and validate AI-based polysomnography (PSG) algorithms to support more accurate and scalable diagnosis of narcolepsy type 1 (NT1). Upon successful validation and regulatory clearance, EnsoData will pursue the clinical availability and release of AI algorithms to enable future access, use, […]
Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system (hypoglossal nerve stimulation) for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Genio is […]
Insurance coverage and reimbursement for home sleep testing (HST) devices have improved in leaps and bounds over the last two decades, but unfortunately, denials and delays in care remain far too common. For many providers, figuring out a way forward can feel like navigating a labyrinth of policies and red […]
Dormotech, a leader in advancing sleep diagnostics through innovative, clinically validated solutions, emphasized the urgent need for early and accessible diagnosis of sleep disorders in children. This critical focus echoes the profound insights shared by globally respected pediatric sleep medicine expert, Dr. Asher Tal. In an in-depth interview with Dormotech, […]
Narcolepsy research is entering an exciting phase, with promising new treatments and discoveries on the horizon. Because narcolepsy symptoms can cause daily disruptions, affecting everything from work to relationships, having effective treatments makes a meaningful difference in improving quality of life. At Wake Up Narcolepsy (WUN), we’re committed to not […]
Sleep and wakefulness are carefully balanced by a network of brain regions. Yet for many years, scientists couldn’t pinpoint exactly which neurons regulated sleep state transitions. New research tools and a deeper understanding of brain signaling have led to new discoveries in dopamine and norepinephrine signaling, offering novel insights into […]
Apnimed, Inc. has announced positive topline results from its second pivotal Phase 3 clinical trial of Apnimed’s lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg). LunAIRo was a 12-month study that evaluated the efficacy and safety of AD109 in adults with mild, moderate and severe OSA, across a wide range of weight […]
Alkermes plc today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly referred to as ALKS 2680, is the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as […]
Sleep apnea is a widespread sleep disorder affecting millions of Americans, yet many cases remain undiagnosed and untreated. Although the practice of screening patients with a home sleep test device by dentists is highly debated, as a board-certified sleep physician I firmly believe that dentists can play a crucial role […]
